Nov 05, 2024 / 10:00AM GMT
Kristian Villumsen - Coloplast A/S-President - Chief Executive Officer, Member of the Executive Management
Thank you very much, operator. Good morning, and welcome to our full year '23, '24 conference call. I am Kristian Villumsen, the CEO of Coloplast, and I'm joined by our CFO, Anders Lonning-Skovgaard, and our Investor Relations team. We'll start with a short presentation by Anders and myself and then open up for questions as we usually do.
Please turn to slide number 3. We delivered 8% organic growth and a reported EBIT margin before special items of 27% for the '23, '24 financial year. Return on invested capital after tax and before special items was 15%, reflecting impact from the acquisition of Kerecis. This year, we continue to help millions of people within healthcare needs, and we also welcome more than 270,000 new users to our support program, Coloplast care.
In our fourth quarter, we delivered organic growth of 8% and a reported EBIT margin before special items of 26%. Anders will take you through the details later, but the EBIT
Q4 2024 Coloplast A/S Earnings Call Transcript
Nov 05, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers